| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 24.05.
| Boston CEO Conference to Feature CEOs of Alkermes, Alnylam, Ariad, Biogen, Cubist, Genzyme, Millennium, Momenta, Sirtris, and Others June 11th and 12th | | 59 | Business Wire |
| More than 200 leading CEOs will gather at the 2012 CEO Conference June 11th
and 12th at the Mandarin Oriental Hotel in Boston.
The Boston CEO Conference is...
Mehr lesen zu:
Boston CEO Conference to Feature CEOs of Alkermes, Alnylam, Ariad, Biogen, Cubist, Genzyme, Millennium, Momenta, Sirtris, and Others June 11th and 12th | |
| 24.05.
| Biogen: Kaufen - Ein Aufwärtstrend wie an der Schnur gezogen ! | | 135 | Chart & Rat |
| Chartanalyse der Biogen Idec - Aktie Abgesehen von mehreren leichten Übertreibungsphasen nach oben bewegt sich die Biogen Aktie in einem langfristigen intakten Aufwärtstrendkanal. Diese Kursentwicklung...
Mehr lesen zu:
Biogen: Kaufen - Ein Aufwärtstrend wie an der Schnur gezogen ! | |
| 24.05.
| Health Canada approves Biogen Tysabri label change | | 1 | Pharma Bus Review |
| 24.05.
| Biogen: Kaufen - Ein Aufwärtstrend wie an der Schnur gezogen ! | | 7 | financial.de |
| 23.05.
| Biogen Says Health Canada Approves Updates To TYSABRI Product Monograph | | 39 | AFX News |
| WESTON (dpa-AFX) - Biogen Idec (BIIB) announced that Health Canada has
approved a product monograph change for TYSABRI that will help enable individual
benefit risk assessment for patients...
Mehr lesen zu:
Biogen Says Health Canada Approves Updates To TYSABRI Product Monograph | |
| 21.05.
| The Zacks Analyst Blog Highlights: Dr. Reddy's Laboratories, Bristol-Myers Squibb, Teva Pharmaceutical, Biogen Idec and Elan | | 56 | PR Newswire |
| CHICAGO, May 21, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting...
Mehr lesen zu:
The Zacks Analyst Blog Highlights: Dr. Reddy's Laboratories, Bristol-Myers Squibb, Teva Pharmaceutical, Biogen Idec and Elan | |
| 21.05.
| Biogen Idec Earnings Hindsight: Down 0.3% in Last 20 Days | | 2 | SmarTrend |
| 18.05.
| Data on Elan & Biogen's Tysabri | | 14 | Zacks |
| 18.05.
| Critical Alerts For Qualcomm, Simon Property, Silver Wheaton, Biogen Idec, and Nu Skin Released By InvestorsObserver | | 113 | PR Newswire |
| CHICAGO, May 18, 2012 /PRNewswire/ --InvestorsObserver issues critical PriceWatch Alerts for QCOM, SPG, SLW, BIIB, and NUS.
To see what our analysts have discovered about these stocks read the...
Mehr lesen zu:
Critical Alerts For Qualcomm, Simon Property, Silver Wheaton, Biogen Idec, and Nu Skin Released By InvestorsObserver | |
| 17.05.
| Biogen Idec Bearish Moving Average Crossover Alert | | 12 | SmarTrend |
| 17.05.
| While U.S. Patients Report High Levels of Satisfaction with Current DMAs, Switching Interest is Highest among Patients for Sanofi / Genzyme's Teriflunomide and Biogen Idec's BG-12, According to a Recent BioTrends Report | | 35 | Business Wire |
| BioTrends Research Group, one of the world's leading research and
advisory firms for specialized biopharmaceutical issues, finds that
patients diagnosed with multiple...
Mehr lesen zu:
While U.S. Patients Report High Levels of Satisfaction with Current DMAs, Switching Interest is Highest among Patients for Sanofi / Genzyme's Teriflunomide and Biogen Idec's BG-12, According to a Recent BioTrends Report | |
| 16.05.
| How High Can Biogen Idec Fly? | | 19 | Motley Fool |
| 15.05.
| 41.6% Return Seen to Date on SmarTrend Biogen Idec Call | | 7 | SmarTrend |
| 14.05.
| Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's, Biogen Idec, Abbott, Novartis | | 75 | PR Newswire |
| CHICAGO, May 14, 2012 /PRNewswire/ --Zacks Equity Research highlights Eastman Chemical (NYSE:EMN) as the Bull of the Day and Kirkland's (Nasdaq:KIRK) as the Bear of the Day. In addition, Zacks Equity...
Mehr lesen zu:
Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's, Biogen Idec, Abbott, Novartis | |
| 14.05.
| Biogen Idec Earnings In Retrospect: Up 3.6% in the Last 13 Days | | - | SmarTrend |
| 14.05.
| Biogen Idec: New AVONEX Dosing Innovations For MS Patients Now Available In US | | 36 | AFX News |
| WESTON (dpa-AFX) - Biogen Idec (BIIB) said two new dosing innovations
designed to help patients receiving once-a-week AVONEX for relapsing forms of
multiple sclerosis, or MS, are now available...
Mehr lesen zu:
Biogen Idec: New AVONEX Dosing Innovations For MS Patients Now Available In US | |
| 14.05.
| Following the Release of Detailed Results from the CONFIRM Study at the 64th Annual Meeting of the American Academy of Neurology, 90 Percent of Surveyed U.S. Neurologists Report Willingness to Prescribe Biogen Idec's BG-12 | | 30 | Business Wire |
| Decision Resources Offers Rapid Assessment of Evolving Physician
Opinion on New Data and Recent Developments in Multiple Sclerosis
Decision Resources...
Mehr lesen zu:
Following the Release of Detailed Results from the CONFIRM Study at the 64th Annual Meeting of the American Academy of Neurology, 90 Percent of Surveyed U.S. Neurologists Report Willingness to Prescribe Biogen Idec's BG-12 | |
| 11.05.
| Standard Review for Biogen's BG-12 | | 9 | Zacks |
| 11.05.
| BIOGEN IDEC - Von Rekord zu Rekord | | 48 | GodmodeTrader.de |
| 09.05.
| Biogen Idec Announces US and EU Regulatory Authorities Accept Oral BG-12 Marketing Applications for Review | | 9 | Benzinga.com |
